Duravyu (vorolanib intravitreal insert)

Name: Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: AREDS2 antioxidant vitamin and mineral supplementation
Published: 2026-09-17T18:16:06-04:00

Wet age-related macular degeneration

Also known as EYP-1901

Manufacturer: EyePoint
Regulatory submission: NDA planned for the first half of 2027
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

AREDS2 antioxidant vitamin and mineral supplementation

1 evidence topic · 1 source

Fellow-eye risk reduction in unilateral neovascular AMD

“Treatment with antioxidants and minerals as described previously in the original AREDS and AREDS2 trials should be considered for patients who have progressed to intermediate or advanced AMD in at least one eye.” (opens the source at this quote in a new tab)
“For patients with unilateral disease, the fellow eye without MNV remains at high risk of developing advanced AMD.” (opens the source at this quote in a new tab)
“The risk can be lowered by as much as 36% over a 10-year period by taking the AREDS/AREDS2 supplements.” (opens the source at this quote in a new tab)